



FIRST INTERNATIONAL NANOTECHNOLOGY CONFERENCE ON COMMUNICATION AND COOPERATION

Abstract

Panel Discussion – Gregory Downing

The National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer (<http://nano.cancer.gov>) is an integrated \$144.3 million, five-year initiative to develop and apply nanotechnology to cancer prevention, detection, diagnosis and treatment. The Alliance will encompass researchers, clinicians, and public and private organizations that have joined forces to translate cancer-related nanotechnology research into clinical practice. Four major programs comprise the Alliance initiative: Centers of Cancer Nanotechnology Excellence, nanotechnology platform for cancer research, multidisciplinary research team and career development, and the Nanotechnology Characterization Laboratory (<http://ncl.cancer.gov>).

Nanotechnology has already demonstrated promising results in cancer research and treatment. This initiative builds on the scientific advances in genomics and proteomics and our understanding of the molecular underpinnings of cancer by facilitating cross-disciplinary and cross-sector collaboration with nanotechnology, which is ripe for biomedical research.

The NCI Alliance for Nanotechnology in Cancer is an integrated, milestone-driven, and product-oriented initiative that aims to capitalize on the opportunities afforded by nanotechnology to create the tools needed by both researchers and clinicians in the fight against cancer.